Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8WYA6
UPID:
CTBL1_HUMAN
Alternative names:
Nuclear-associated protein; Testis development protein NYD-SP19
Alternative UPACC:
Q8WYA6; B4DE16; Q0VAL9; Q0VAM0; Q53HI8; Q5JWZ2; Q5JWZ3; Q5JWZ7; Q5JWZ8; Q8N454; Q8NCL2; Q8TBD6; Q96KD2; Q9H7A5; Q9NQF9; Q9NTX0; Q9Y3M7
Background:
Beta-catenin-like protein 1, also known as Nuclear-associated protein and Testis development protein NYD-SP19, plays a crucial role in the PRP19-CDC5L complex integral to the spliceosome, activating pre-mRNA splicing. It is pivotal in somatic hypermutation and class-switch recombination, essential for producing high-affinity, mutated, isotype-switched antibodies.
Therapeutic significance:
Linked to Immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias, Beta-catenin-like protein 1's understanding could pave the way for innovative therapeutic strategies targeting immune system disorders.